medigraphic.com
Boletín Médico del Hospital Infantil de México

2019, Number 4

<< Back Next >>

Bol Med Hosp Infant Mex 2019; 76 (4)

Infantile hemangioma: an update in the topical and systemic treatments

Cheirif-Wolosky O, Novelo-Soto AD, Orozco-Covarrubias L, Sáez-de-Ocariz M

Language: Spanish
References: 59
Page: 167-175
PDF size: 231.80 Kb.


ABSTRACT

Infantile hemagiomas (IH) are the most common soft tissue tumors in infancy. They are characterized by significant growth during the first months of life, followed by slow spontaneous involution over the ensuring years. The process of involution takes several years, but usually the regression of most of the tumors ends at 4 years of age. Unfortunately, some of the IH develop complications, resulting in functional impairment, pain and disfigurement. The decision to start treatment and the choice of the best therapeutic option (topic or systemic) should be individualized depending on several factors: the size of the lesion, the location, the presence of complications such as ulceration, the risk of scarring or disfigurement, the age of the patient, the rate of growth or regression at the time of diagnosis, the risks and benefits of the treatment, the availability of the medication, the costs, and the experience of the attending physician.


REFERENCES

  1. Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25: 168-73.

  2. Hoornweg MJ, Smeulders MJ, Ubbink DT, Van Der Horst CM. The prevalence and risk factors for infantile haemangiomas: a case-control study in the Dutch population. Paediatr Perinat Epidemiol. 2012;26:156-62.

  3. Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Hemangioma Investigator Group. Prospective study of infantile hemangiomas: demographic, prenatal and perinatal characteristics. J Pediatr. 2007;150:291-4.

  4. Giachetti A, Sojo MM, García-Mónaco R. Hemangiomas infantiles. Arch Argent Pediatr. 2013;111:537-45.

  5. Drolet BA, Swanson EA, Frieden IJ, Hemangioma Investigator Group. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr. 2008;153:712-5.

  6. Darrow DH, Greene AK, Mancini AJ, Nopper AJ, Section on dermatology, section on otolaryngology—head and neck surgery, and section on plastic surgery. Diagnosis and management of infantile hemangioma. Pediatrics. 2015;136:e1060-104.

  7. Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Hemangioma Investigator Group. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122:360-7.

  8. Smithson SL, Rademaker M, Adams S, Bade S, Bekhor P, Davidson S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. Australas J Dermatol. 2017;58:155-9.

  9. Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol. 2010;128:255-6.

  10. Ni N, Langer P, Wagner R, Guo S. Topical timolol for periocular hemangioma: Report of further study. Arch Ophthalmol. 2011;129:377-9.

  11. Semkova K, Kazandjieva J. Topical timolol maleate for treatment of infantile haemangiomas: Preliminary results of a prospective study. Clin Exp Dermatol. 2013;38:143-6.

  12. Fernández-Ballesteros MD, Vera-Casaño A, Escudero-Gómez J, Hiraldo- Gamero A. Infantile hemangioma of the eyelid treated with timolol gel. Actas Dermosifiliogr. 2012;103:444-6.

  13. Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial hemangiomas in 5-to 24 weeks-olds. Pediatrics. 2013;131:1739-47.

  14. Sethuraman G, Yenamandra V, Gupta V. Management of infantile hemangiomas: Current Trends. J Cutan Aesthet Surg. 2014;7:75-85.

  15. Kunzi-Rapp K. Topical propranolol therapy for infantile hemangiomas. Pediatr Dermatol 2012;29:154-9.

  16. Xu G, Lv R, Zhao Z, Huo R. Topical propranolol for treatment of superficial infantile hemangiomas. J Am Acad of Dermatol. 2012;67:1210-3.

  17. Kovačević M, Lukinović V, Maričić G, Krnjević-Pezić G, Stanimirović A. Topical propranolol cream in treatment of superficial infantile hemangiomas: a literature review and 4 years of clinical experience. Acta Dermatovenerol Alp Pannonica Adriat. 2014;23:75-8.

  18. Li WV, Li W, Talcott EK, Zhai W. Imiquimod as an antiangiogenic agent. J Drugs Dermatol. 2005;4:708-17.

  19. Qiu Y, Ma G, Yang J, Hu X, Chen H, Jin Y, et al. Imiquimod 5% vs cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study. Clin Exp Dermatol. 2013;38:845-50.

  20. Martínez MI, Sánchez-Carpintero I, North PE, Mihm MC Jr. Infantile hemangioma: Clinical resolution with 5% imiquimod cream. Arch dermatol. 2002;138:881-4.

  21. Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol. 2007;56:63-8.

  22. McCuaig CC, Dubois J, Powell J, Belleville C, David M, Rousseau E, et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol. 2009;26:203-12.

  23. Elsas FJ, Lewis AR. Topical treatment of perioocular capillary hemangioma. J Pediatr Ophtalmol Strabismus. 1994;31:4-7.

  24. Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol. 2005;52:281-6.

  25. Fowler J, Jarrat M, Moore A, Meadows K, Pollack A, Steinhoff M, et al. Once daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle controlled studies. Br J Dermatol. 2012;166:633-41.

  26. Chu MB, Searcy G, Siegfried E. Efficacy of topical brimonidine-timolol for haemangioma of infancy and perils of off-label prescribing. BMJ Case Rep. 2013: bcr2013009365. doi: 10.1136/bcr-2013-009365.

  27. Beal BT, Chu MB, Siegfried EC. Ulcerated infantile hemangioma: novel treatment with topical brimonidine-timolol. Pediatr Dermatol 2014;31:754-6.

  28. Gil K, Bayart C, Desai R, Golden A, Raimer P, Tamburro J. Brimonidine toxicity secondary to topical use for an ulcerated hemangioma. Pediatr Dermatol. 2016;33:232-4.

  29. Lai Becker M, Huntington N, Woolf AD. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. Pediatrics. 2009;123:e305-11.

  30. Sánchez-Carpintero I, Mihm MC, Waner M. [Laser and intense pulsed light in the treatment of infantile haemangiomas and vascular malformations]. An Sist Sanit Navar. 2004;27:103-15.

  31. Poetke M, Philipp C, Berlien HP. Flashlamp-pumped pulsed dye laser for hemangiomas in infancy: treatment of superficial vs. mixed hemangiomas. Arch Dermatol. 2000;136:628-32.

  32. Raulin C, Greve B. Retrospective clinical comparison of hemangioma treatment by flashlamp-pumped (585 nm) and frequency-doubled Nd: YAG (532 nm) lasers. Lasers Surg Med. 2001;28:40-3.

  33. Burstein FD, Williams JK, Schwentker AR, Nahai F. Intralesional laser therapy treatment for hemangiomas: technical evolution. J Craniofac Surg. 2006;17:756-60.

  34. Katz HP, Askin J. Multiple hemangiomata with thrombopenia: an unusual case with comments on steroid therapy. Am J Dis Child. 1968;115:351-7.

  35. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326: 1456-63.

  36. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649-51.

  37. Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw- Hautier J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009;124:423-31.

  38. Liu LS, Sokoloff D, Antaya RJ. Twenty-four-hour hospitalization for patients initiating systemic propranolol therapy for infantile hemangiomas— is it indicated? Pediatr Dermatol. 2013;30:554-60.

  39. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128:e259-66.

  40. Pope E, Chakkittakandiyil A, Lara-Corrales I, Maki E, Weinstein M. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol. 2013;168:222-4.

  41. Itinteang T, Withers AH, Davis PF, Tan ST. Biology of infantile hemangioma. Front Surg. 2014;1:38.

  42. Dai Y, Hou F, Buckmiller L, Fan CY, Saad A, Suen J, et al. Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas. Arch Otolaryngol Head Neck Surg. 2012;138:177-82.

  43. Ji Y, Chen S, Xu C, Li L, Xiang B. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2015;172:24-32.

  44. Léauté-Labrèze C, Hoeger P, Mazereeuw- Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735-46.

  45. Starkey E, Shahidullah H. Propranolol for infantile haemangiomas: a review. Arch Dis Child. 2011;96:890-3.

  46. Lou Y, Peng WJ, Cao Y, Cao DS, Xie J, Li HH. The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. Br J Clin Pharmacol. 2014;78:44-57.

  47. Vivas-Colmenares GV, Bernabeu-Wittel J, Alonso-Arroyo V, Matute de Cardenas JA, Fernandez-Pineda I. Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase. Pediatr Dermatol. 2015;32:348-52.

  48. Raphael MF, Breugem CC, Vlasveld FA, de Graaf M, Slieker MG, Pasmans SG, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas? A cohort study. J Am Acad Dermatol. 2015;72:465-72.

  49. Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128-40.

  50. Blei F, McElhinney DB, Guarini A, Presti S. Cardiac screening in infants with infantile hemangiomas before propranolol treatment. Pediatr Dermatol. 2014;31:465-70.

  51. Raphael MF, de Graaf M, Breugem CC, Pasmans SGMA, Breur JMPJ, et al. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas. J Am Acad Dermatol. 2011;65:420-1.

  52. De Graaf M, Raphael MF, Breugem CC, Knol MJ, Bruijnzeel-Koomen CA, Kon M, et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. J Plast Reconstr Aesthet Surg. 2013;66:1732-40.

  53. Abarzua-Araya A, Navarrete-Dechent CP, Heusser F, Retamal J, Zegpi-Trueba MS. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol. 2014;70:1045-9.

  54. Ji Y, Wang Q, Chen S, Xiang B, Xu Z, Li Y, et al. Oral atenolol therapy for proliferating infantile hemangioma: a prospective study. Medicine (Baltimore). 2016;95:e3908.

  55. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137:1208-13.

  56. Kelly ME, Juern AM, Grossman WJ, Schauer DW, Drolet BA. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol. 2010;146:767-74.

  57. Kim KH, Choi TH, Choi Y, Park YW, Hong KY, Kim DY, et al. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. JAMA Dermatol. 2017;153:529-36.

  58. Enjolras O, Brevière GM, Roger G, Tovi M, Pellegrino B, Varotti E, et al. [Vincristine treatment for function- and life-threatening infantile hemangioma]. Arch Pediatr. 2004;11:99-107.

  59. Greene AK. Management of hemangiomas and other vascular tumors. Clin Plast Surg. 2011;38:45-63.




2020     |     www.medigraphic.com